PT4117667T - Tratamento sequencial de cancros utilizando 6-tio-dg e inibidores de ponto de verificação - Google Patents

Tratamento sequencial de cancros utilizando 6-tio-dg e inibidores de ponto de verificação

Info

Publication number
PT4117667T
PT4117667T PT217671254T PT21767125T PT4117667T PT 4117667 T PT4117667 T PT 4117667T PT 217671254 T PT217671254 T PT 217671254T PT 21767125 T PT21767125 T PT 21767125T PT 4117667 T PT4117667 T PT 4117667T
Authority
PT
Portugal
Prior art keywords
thio
cancers
radiation therapy
checkpoint inhibitors
sequential treatment
Prior art date
Application number
PT217671254T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of PT4117667T publication Critical patent/PT4117667T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PT217671254T 2020-03-13 2021-03-12 Tratamento sequencial de cancros utilizando 6-tio-dg e inibidores de ponto de verificação PT4117667T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062989041P 2020-03-13 2020-03-13

Publications (1)

Publication Number Publication Date
PT4117667T true PT4117667T (pt) 2025-02-06

Family

ID=77671975

Family Applications (1)

Application Number Title Priority Date Filing Date
PT217671254T PT4117667T (pt) 2020-03-13 2021-03-12 Tratamento sequencial de cancros utilizando 6-tio-dg e inibidores de ponto de verificação

Country Status (17)

Country Link
US (2) US12097213B2 (https=)
EP (1) EP4117667B1 (https=)
JP (1) JP7829491B2 (https=)
KR (1) KR20220154134A (https=)
CN (1) CN115397428A (https=)
AU (1) AU2021233023B2 (https=)
BR (1) BR112022018238A2 (https=)
CA (1) CA3170930A1 (https=)
DK (1) DK4117667T3 (https=)
ES (1) ES3014683T3 (https=)
FI (1) FI4117667T3 (https=)
HU (1) HUE070513T2 (https=)
IL (1) IL296403A (https=)
MX (1) MX2022011331A (https=)
PL (1) PL4117667T3 (https=)
PT (1) PT4117667T (https=)
WO (1) WO2021183873A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183482A1 (en) 2018-03-22 2019-09-26 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
WO2025090539A1 (en) * 2023-10-22 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052181A1 (en) * 2010-10-22 2012-04-26 Roche Diagnostics Gmbh A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide
CA2907924C (en) 2013-04-08 2022-10-25 The Board Of Regents Of The University Of Texas System Telomerase mediated telomere altering compounds
CN116059219A (zh) * 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
US20180036331A1 (en) 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3463370A4 (en) * 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL
KR20190053909A (ko) 2016-09-16 2019-05-20 바이오노믹스 리미티드 항체와 체크포인트 면역 억제제의 병용 요법
KR20240011262A (ko) * 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
JP2020515637A (ja) 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
WO2019152574A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
US20210113602A1 (en) 2018-02-28 2021-04-22 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA
WO2019183482A1 (en) * 2018-03-22 2019-09-26 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS

Also Published As

Publication number Publication date
US12097213B2 (en) 2024-09-24
IL296403A (en) 2022-11-01
JP2023517671A (ja) 2023-04-26
EP4117667A4 (en) 2023-11-15
EP4117667A1 (en) 2023-01-18
AU2021233023B2 (en) 2026-04-16
DK4117667T3 (da) 2025-02-10
ES3014683T3 (en) 2025-04-24
BR112022018238A2 (pt) 2022-10-25
PL4117667T3 (pl) 2025-04-07
CA3170930A1 (en) 2021-09-16
CN115397428A (zh) 2022-11-25
AU2021233023A1 (en) 2022-11-03
EP4117667B1 (en) 2024-12-18
HUE070513T2 (hu) 2025-06-28
KR20220154134A (ko) 2022-11-21
FI4117667T3 (fi) 2025-02-10
US20210290652A1 (en) 2021-09-23
MX2022011331A (es) 2022-10-27
JP7829491B2 (ja) 2026-03-13
WO2021183873A1 (en) 2021-09-16
US20240424013A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
IL284324A (en) Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer
IL284326A (en) Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer
IL288395A (en) Mat2a tricyclic inhibitors and methods for use in cancer therapy
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
IL277665A (en) Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy
IL290123A (en) Combined treatment including antibodies against claudin 18.2 and immune checkpoint inhibitors for cancer treatment
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
AU2018302999A1 (en) Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy
IL307964A (en) Combined treatment for cancer
PL4225297T3 (pl) Terapia skojarzona w leczeniu nowotworu złośliwego
IL312546A (en) Adaptation of equipment and methods for photodynamic therapy
PT4117667T (pt) Tratamento sequencial de cancros utilizando 6-tio-dg e inibidores de ponto de verificação
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
EP4319729A4 (en) CANCER TREATMENT WITH PARP INHIBITORS AND PLK1 INHIBITORS
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
IL291092A (en) Cancer treatment using a combination containing a multi-tyrosine kinase inhibitor and an immune barrier inhibitor
IL279591A (en) Cancer treatment methods using combination therapy
IL288178A (en) Combined gmci and ddri treatment for cancer
IL275913A (en) Methods and combined treatment for cancer treatment
IL309487A (en) Methods for determining the effectiveness of cancer treatment
GB202101728D0 (en) Compounds and their use treating cancer
IL312899A (en) Combined treatment for cancer
IL300106A (en) Combination therapy for cancer treatment
IL321145A (en) Combination therapy for cancer treatment that includes anti-PD-L1 and anti-CD73 antibodies
HK40118674A (en) Use of combination therapy for treating cancer